Gene · 5142
Papers1,785
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,785
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PDE4B promotes JNK/NLRP3 activation in the nucleus pulposus and mediates intervertebral disc degeneration. | Sci Rep | 2025 | 39962094 | PubTator, text mining | PubMed |
| Drug repositioning based on mutual information for the treatment of Alzheimer's disease patients. | Med Biol Eng Comput | 2025 | 39961913 | PubTator, text mining | PubMed |
| PDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury. | Lung | 2025 | 39956855 | PubTator, text mining | PubMed |
| PDE4B promotes ferroptosis in nucleus pulposus cells and is involved in intervertebral disc degeneration. | Sci Rep | 2025 | 39893206 | PubTator, text mining | PubMed |
| Pde4b-regulated cAMP signaling pathway in the AUDGABA-S1TrSst circuit underlies acute-stress-induced anxiety-like behavior. | Cell Rep | 2025 | 39891910 | PubTator, text mining | PubMed |
Corrigendum to "PDE4B abrogation extenuates angiotensin II-induced endothelial dysfunction related to hypertension through up-regulation of AMPK/Sirt1/Nrf2/ARE signaling" [Tissue Cell 91 (2024) 102637]. | Tissue Cell | 2025 | 39818485 | PubTator, text mining | PubMed |
| Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. | Ther Adv Respir Dis | 2025 | 39745090 | PubTator, text mining | PubMed |
| COF-SO3H-Catalyzed Synthesis of Pyrazoline-Pyridine Hybrids with Dual Antioxidant and Anti-Inflammatory Activity Targeting PDE4B. | Chem Biodivers | 2025 | 39523465 | PubTator, text mining | PubMed |
| Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases. | Clin Exp Rheumatol | 2025 | 39212123 | PubTator, text mining | PubMed |
| A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases. | Hepatology | 2025 | 38950389 | PubTator, text mining | PubMed |
| PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review. | Open Respir Med J | 2024 | 39839967 | PubTator, text mining | PubMed |
| Promising candidate drug target genes for repurposing in cervical cancer: A bioinformatics-based approach. | Narra J | 2024 | 39816079 | PubTator, text mining | PubMed |
| Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. | RMD Open | 2024 | 39719300 | PubTator, text mining | PubMed |
Machine Learning Integration with Single-Cell Transcriptome Sequencing Datasets Reveals the Impact of Tumor-Associated Neutrophils on the Immune Microenvironment and Immunotherapy Outcomes in Gastric Cancer. | Int J Mol Sci | 2024 | 39684426 | PubTator, text mining | PubMed |
| PDE4B abrogation extenuates angiotensin II-induced endothelial dysfunction related to hypertension through up-regulation of AMPK/Sirt1/Nrf2/ARE signaling. | Tissue Cell | 2024 | 39591723 | PubTator, text mining | PubMed |
| Unveiling the role of phytochemicals in autism spectrum disorder by employing network pharmacology and molecular dynamics simulation. | Metab Brain Dis | 2024 | 39570464 | PubTator, text mining | PubMed |
| Identifying a CD8T cell signature in the tumor microenvironment to forecast gastric cancer outcomes from sequencing data. | J Gastrointest Oncol | 2024 | 39554559 | PubTator, text mining | PubMed |
| Rationale design and synthesis of new roflumilast analogues as preferential selective and potent PDE-4B inhibitors. | Bioorg Chem | 2024 | 39467506 | PubTator, text mining | PubMed |
| Exploring the material basis and molecular targets of Changma Xifeng tablet in treating Tourette syndrome: an integrative approach of network pharmacology and miRNA analysis. | Metab Brain Dis | 2024 | 39436634 | PubTator, text mining | PubMed |
| GZMA suppressed GPX4-mediated ferroptosis to improve intestinal mucosal barrier function in inflammatory bowel disease. | Cell Commun Signal | 2024 | 39367435 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5142/papers?page=6